Skip to main content

Part of the book series: Contemporary Endocrinology ((COE))

  • 146 Accesses

Abstract

The gonads in both sexes serve the same dual functions, namely, the production of gametes and sex steroids. These functions are clinically quiescent in children but subsequently are induced at puberty and then maintained through much of adulthood by the glycoprotein pituitary gonadotropins leutinizing hormone (LH) and follicle-stimulating hormone (FSH). By historical convention these names refer to events and structures within the ovary, but their structures are identical in both men and women and their functions in each gender are largely similar. The secretions of these gonadotropins are largely regulated by classic feedback inhibition from circulating gonadal products, with LH being excreted by the sex steroid levels in blood and FSH by proteins (inhibins) produced by developing gametes (Fig. 1). When inadequate gonadal function results from a defect within the gonad itself, the condition is referred to as primary gonadal failure. Hypogonadism resulting from pituitary or hypothalamic defects is referred to as secondary and tertiary gonadal failure, respectively. Despite the later distinction, many authors continue to refer to either pituitary or hypothalamic failure as secondary or “central” hypogonadism.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Tansey MJ, Schlechte JA. Pituitary production of prolactin and prolactin-suppressing drugs. Lupus 2001:10:660–664.

    Article  PubMed  CAS  Google Scholar 

  2. Loprinzi CL, Michalak JC, Quella SK. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347–352.

    Article  PubMed  CAS  Google Scholar 

  3. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000;132:788–793.

    PubMed  CAS  Google Scholar 

  4. Stearns V, Isaacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000;11:17–22.

    Article  PubMed  CAS  Google Scholar 

  5. David A, Don R, Tajchner G, Weissglas L. Veralipride: alternative antidopaminergic treatment for menopausal symptoms. Am J Obstet Gynecol 1988;158:1107–1115.

    PubMed  CAS  Google Scholar 

  6. Moghissi KS. Hormone replacement therapy for menopausal women. Compr Ther 2000;26:197–202.

    Article  PubMed  CAS  Google Scholar 

  7. Yaffe K. Estrogens, selective estrogen receptor modulators, and dementia: what is the evidence? Ann NY Acad Sci 2001;949:215–222

    Google Scholar 

  8. Halbreich U, Kahn LS. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs 2001;15:797–817

    Article  PubMed  CAS  Google Scholar 

  9. Bachmann G. Physiologic aspects of natural and surgical menopause. J Reprod Med 2001;46(3 suppl):307–315.

    PubMed  CAS  Google Scholar 

  10. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933–941.

    PubMed  CAS  Google Scholar 

  11. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102–1109.

    Article  PubMed  CAS  Google Scholar 

  12. Petitti DB, Perlman JA, Sidney S. Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol 1987;70:289–293.

    PubMed  CAS  Google Scholar 

  13. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75–78.

    Article  PubMed  CAS  Google Scholar 

  14. Psaty BM, Hackbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogen and progestin in postmenopausal women. Arch Intern Med 1994;154:1333–1339.

    Article  PubMed  CAS  Google Scholar 

  15. Hulley S, Grady, D Bush T, et al., for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605–613.

    Article  PubMed  CAS  Google Scholar 

  16. Cherry N. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet 2002;360:2001–2008.

    Article  PubMed  CAS  Google Scholar 

  17. Manson JE, Martin KA. Clinical practice. Postmenopausal hormone-replacement therapy. N Engl J Med 2001;345:34.

    Article  PubMed  CAS  Google Scholar 

  18. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001;104:499.

    Article  PubMed  CAS  Google Scholar 

  19. Writing group for the Women’s Health Initiative investigators, Risks and benefits of estrogen plus progestin in healthy women; Principal results from the Women’s Health Initiative Randomized Controlled Trial. JAMA 2002;288:321–333.

    Google Scholar 

  20. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065–1079.

    Article  PubMed  CAS  Google Scholar 

  21. Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999;131:935–942.

    PubMed  CAS  Google Scholar 

  22. Bardin CW, Lipsett MB. Testosterone and androstenedione blood production rates in normal women and women with idiopathic hirsutism or polycystic ovaries. J Clin Invest 1967;46:891.

    Article  PubMed  CAS  Google Scholar 

  23. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682–688.

    Article  PubMed  CAS  Google Scholar 

  24. Watts, NB, Notelovitz, M, Timmons, MC, et al. Comparison of oral estrogens and estrogen plus androgen on bone mineral density, menopausal symptoms and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 1995;85:529.

    Article  PubMed  CAS  Google Scholar 

  25. Benvenga S, Campenni A, Ruggeri RM, Trimarchi F. Hypopituitarism secondary to head trauma. J Clin Endocrinol Metab 2000;85:p-1361.

    Article  Google Scholar 

  26. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87:589–598.

    Article  PubMed  CAS  Google Scholar 

  27. Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000;49:1239–242.

    Article  PubMed  CAS  Google Scholar 

  28. Summary of the Consensus Session from the 1st Annual Andropause Consensus 2000 Meeting, the Endocrine Society.

    Google Scholar 

  29. Singh AB, Hsia S, Alaupovic P, et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 2002;87:136–143.

    Article  PubMed  CAS  Google Scholar 

  30. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997;82:3793–3796.

    Article  PubMed  CAS  Google Scholar 

  31. Viallard JF, Marit G, Mercie P, Leng B, Reiffers J, Pellegrin JL. Polycythaemia as a complication of transdermal testosterone therapy. Br J Haematol 2000;110:237–238.

    Article  PubMed  CAS  Google Scholar 

  32. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999;84:3469–3478

    Article  PubMed  CAS  Google Scholar 

  33. Bhasin S, ed. The Endocrine Society Clinical Bulletins in Andropause: Benefits and Risks of Treating Hypogonadism in the Aging Male, no. 2, 2002.

    Google Scholar 

  34. Gambineri A, Pasquali R. Testosterone therapy in men: clinical and pharmacological perspectives. J Endocrinol Invest 2000;23:196–214

    PubMed  CAS  Google Scholar 

  35. Zitzmann M, Nieschlag E. Hormone substitution in male hypogonadism. Mol Cell Endocrinol 2000;161:73–88.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

MacIndoe, J.H. (2003). Hypogonadism in Men and Women. In: Bar, R.S. (eds) Early Diagnosis and Treatment of Endocrine Disorders. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-378-1_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-378-1_17

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-414-2

  • Online ISBN: 978-1-59259-378-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics